Maas Biolab Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

Maas Biolab General Information

Description

Operator of a biotechnology firm intended to develop a neuro-pharmaceutical drug. The company's services develop a treatment for chronic neurodegenerative diseases including amyotrophic lateral sclerosis, Alzheimer's, Parkinson's and Huntington's, enabling healthcare practitioners to access advanced drugs for better treatment.

Contact Information

Website
www.maasbiolab.com
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 23 Abanico Road
  • Santa Fe, NM 87508
  • United States
+1 (505) 000-0000
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • 23 Abanico Road
  • Santa Fe, NM 87508
  • United States
+1 (505) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Maas Biolab Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Secondary Transaction - Private 01-Mar-2021 0000 Completed Generating Revenue
2. Grant 01-Jan-2007 00.000 0000 Completed Generating Revenue
1. Later Stage VC 25-Apr-2006 $50K $50K Completed Generating Revenue
To view Maas Biolab’s complete valuation and funding history, request access »

Maas Biolab Patents

  • 26

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 8

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

Maas Biolab Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2003229835-A1 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier Inactive 22-Feb-2002 000000000
AU-2003229835-A8 Compounds, compositions and method for transporting cyclosporin molecules through the blood brain barrier Inactive 22-Feb-2002 000000000
FR-2836474-B1 Compounds, compositions and method for transporting cyclosporin molecules through the hematoencephalic barrier Inactive 22-Feb-2002 000000000
FR-2836474-A1 New cyclosporin derivatives, containing bonded peptide vector for crossing blood-brain barrier, used for treating cerebral disorders such as neurodegenerative diseases, cerebral trauma or cerebrovascular accidents Active 22-Feb-2002 000000000 0
US-20040147433-A1 Preparing a dosage of a neuroimmunophilin ligand selected from cyclosporins and functional derivatives, metabolites, variants, and salts thereof which are able to cross the blood-brain barrier; administering that dosage Inactive 14-Jun-2001 A61K38/13 0
To view Maas Biolab’s complete patent history, request access »

Maas Biolab Executive Team (3)

Name Title Board Seat
Marcus Keep MD Chief Executive Officer
Michael Vickers Director of Operations
Eskil Elmér Founder
To view Maas Biolab’s complete executive team members history, request access »

Maas Biolab Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Maas Biolab Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National institutes of Neurological Disorders and Stroke Government 000 0000 000000 0
Small Business Innovation Research and Small Business Technology Transfer Programs Government 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Maas Biolab’s complete investors history, request access »

Ready to get started?

Request a free trial

Maas Biolab FAQs

  • When was Maas Biolab founded?

    Maas Biolab was founded in 1997.

  • Who is the founder of Maas Biolab?

    Eskil Elmér is the founder of Maas Biolab.

  • Who is the CEO of Maas Biolab?

    Marcus Keep MD is the CEO of Maas Biolab.

  • Where is Maas Biolab headquartered?

    Maas Biolab is headquartered in Santa Fe, NM.

  • What is the size of Maas Biolab?

    Maas Biolab has 4 total employees.

  • What industry is Maas Biolab in?

    Maas Biolab’s primary industry is Drug Discovery.

  • Is Maas Biolab a private or public company?

    Maas Biolab is a Private company.

  • What is Maas Biolab’s current revenue?

    The current revenue for Maas Biolab is 000000.

  • How much funding has Maas Biolab raised over time?

    Maas Biolab has raised $50K.

  • Who are Maas Biolab’s investors?

    National institutes of Neurological Disorders and Stroke, Small Business Innovation Research and Small Business Technology Transfer Programs, and U.S. Department of Health and Human Services have invested in Maas Biolab.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »